0 -0.00571133195491232 -0.00270126058827454 -0.00240112052291078 0.000200093376909232 -0.00120056026145539 0.0141065830721004 0.00643633695724674
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance Canada]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance Canada
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
The company, which has a strong foothold in HIV drugs and liver disease treatments, has ?been looking for growth beyond its core areas as it faces declining sales of its COVID-19 drug Veklury and prepares for future patent losses. It will pay $115 per share in cash, which is at a premium of 79% to the stock's last close. Shares of ?Arcellx were trading up 78.5% ?at $114.46 while Gilead fell about 1% before the bell. This is Gilead's biggest deal since its $21 billion buyout of Immunomedics, giving it ?access to Trodelvy, an antibody-drug conjugate used to treat a type of advanced breast cancer. Kite Pharma, a unit of Gilead Sciences, was partnering with Arcellx to jointly develop and ?sell anito-cel - ?an experimental CAR-T therapy for multiple myeloma, ?a type of blood cancer. CAR-T ?cell therapy is a cancer treatment that uses a patient's own genetically modified immune cells to find and kill cancer cells. The U.S. Food and Drug Administration is currently reviewing ani [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance Canada]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance Canada
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
The company, which has a strong foothold in HIV drugs and liver disease treatments, has ?been looking for growth beyond its core areas as it faces declining sales of its COVID-19 drug Veklury and prepares for future patent losses. It will pay $115 per share in cash, which is at a premium of 79% to the stock's last close. Shares of ?Arcellx were trading up 78.5% ?at $114.46 while Gilead fell about 1% before the bell. This is Gilead's biggest deal since its $21 billion buyout of Immunomedics, giving it ?access to Trodelvy, an antibody-drug conjugate used to treat a type of advanced breast cancer. Kite Pharma, a unit of Gilead Sciences, was partnering with Arcellx to jointly develop and ?sell anito-cel - ?an experimental CAR-T therapy for multiple myeloma, ?a type of blood cancer. CAR-T ?cell therapy is a cancer treatment that uses a patient's own genetically modified immune cells to find and kill cancer cells. The U.S. Food and Drug Administration is currently reviewing ani [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS